Merck Serono signs up to Ablynx's Nanobodies
This article was originally published in Scrip
Executive Summary
Ablynx is to receive €10 million in cash upfront from Merck Serono after the latter became the latest partner for the Belgian's firm Nanobodies technology. The two companies will co-discover and co-develop the technology for two targets, in oncology and immunology.